LTR Pharma has officially debuted on the Australian Securities Exchange (ASX) under ticker code LTP.
Our foremost priority is to execute a bioequivalence trial of SPONTAN® to support expedited regulatory approvals, and to market and sell SPONTAN in the United States and Australia, first.
We have a highly experienced team of pharmaceutical developers and commercialisation experts driving this program forward – and valued investors backing us too.
Successful phase I human proof of concept study now complete. SPONTAN® has shown to be six times faster than oral PDE5 inhibitors.
On track to register the first PDE5 inhibitor nasal spray, in a market estimated to reach US$6.0B in 2028.
Progressing to bioequivalence study, with expedited regulatory filings in the United States and Australia within 1-2 years.
View our Shareholder Communications summary here
View our Corporate Directory here
LTR Pharma is pleased to announce it has entered into an agreement with Symbion Pty Ltd, a leading pharmaceutical wholesaler in Australia, to establish national
LTR Pharma is pleased to announce it has entered into an access agreement with Men’s Health Downunder (MHDU) to facilitate access to SPONTAN® through the
LTR Pharma’s joint venture partner Restorative Health Clinic has today launched its online men’s health platform ahead of schedule, delivering comprehensive telehealth services to Australian
9/204 Alice Street, Brisbane QLD 4000
Phone: 1800 519 711